Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

133.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 979
Open 133.86
Bid (Size) 133.00 (2)
Ask (Size) 133.66 (1)
Prev. Close 133.86
Today's Range 133.86 - 133.86
52wk Range 74.75 - 142.00
Shares Outstanding 96,748,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs

Performance

YTD
+8.75%
+8.75%
1 Month
-0.64%
-0.64%
3 Month
+6.70%
+6.70%
6 Month
+59.13%
+59.13%
1 Year
+12.55%
+12.55%

More News

Read More
Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape
Via InvestorPlace
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Via Benzinga
DexCom Inc Chart Analysis
Via Talk Markets
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
NASDAQ:DXCM—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Via InvestorPlace
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
Via Investor's Business Daily
2 Growth Stocks to Buy Hand Over Fist in April
Via The Motley Fool
7 Nasdaq Stocks to Sell in April Before They Crash & Burn
Via InvestorPlace
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
DexCom's Options: A Look at What the Big Money is Thinking
Via Benzinga
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
Via MarketBeat
3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List
Via InvestorPlace
Topics Stocks
Exposures US Equities
Micron, Dropbox And 2 Other Stocks Insiders Are Selling
Via Benzinga
Market Cap Game Show: Andy Cross vs. Bill Mann
Via The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Via Investor's Business Daily
Two Hot AI Stocks Lead S&P 500 Monday
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
Via InvestorPlace
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.